



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Psychiatry*

**Manuscript NO:** 64939

**Title:** Abnormal synaptic plasticity and impaired cognition in schizophrenia

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 01761104

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-26

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2021-03-29 12:10

**Reviewer performed review:** 2021-03-29 14:51

**Review time:** 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

statements

Conflicts-of-Interest: [ ] Yes [Y] No

### **SPECIFIC COMMENTS TO AUTHORS**

The article is timely and important. Here are some minor suggestions: 1. page 13: Clozapine should be clozapine. 2. page 16: in the glutamate section, more details can be addressed. For example, cystine/glutamate antiporter system xc(-) <https://pubmed.ncbi.nlm.nih.gov/26540405/> The authors also mentioned VGLUT2 protein. Other important proteins, such as DAOA (or G72) can be addressed too. <https://pubmed.ncbi.nlm.nih.gov/23857119/> <https://pubmed.ncbi.nlm.nih.gov/32582679/> 3. page 19: In the potential targets to treatment section, the authors can also address other targets such as glycine transporter (sarcosine) <https://pubmed.ncbi.nlm.nih.gov/32122256/> and DAAO (or DAO) <https://pubmed.ncbi.nlm.nih.gov/31660823/>